{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Rash"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Number of participants that experienced the most frequent adverse events of grade 1-2 by CTCAE grading.","groups":[{"description":"Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nlapatinib ditosylate: Given orally\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Lapatinib Ditosylate)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Most Frequent Adverse Events of Grade 1-2 by CTCAE Grading","type":"SECONDARY","unitOfMeasure":"participants"}